Stock MRNA MODERNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Moderna, Inc.

Equities

MRNA

US60770K1079

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-08 EDT 		5-day change 1st Jan Change
121.9 USD +0.68% Intraday chart for Moderna, Inc. +10.50% +22.56%
05-07 UBS Adjusts Moderna Price Target to $151 From $143, Maintains Buy Rating MT
05-06 News Highlights : Top Financial Services News of the Day - Monday at 4 PM ET DJ

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Moderna Insider Sold Shares Worth $1,663,855, According to a Recent SEC Filing
MT
China's drugmakers can't sell mRNA shots but haven't quit yet
RE
Moderna Insider Sold Shares Worth $1,575,300, According to a Recent SEC Filing
MT
Moderna CEO: 'Excited' About Future Following 4Q Revenue
MT
Moderna Insider Sold Shares Worth $936,981, According to a Recent SEC Filing
MT
Moderna Insider Sold Shares Worth $2,342,098, According to a Recent SEC Filing
MT
Lonza chairman to step down, drugmaker confirms targets, shares soar
RE
Moderna Insider Sold Shares Worth $1,558,500, According to a Recent SEC Filing
MT
Stéphane Bancel, CEO of Moderna: Restoring confidence in the vaccines sector
MT
Top Stories at Midday: Boeing Declines After FAA Grounding; Twilio Names New CEO; Johnson & Johnson May Pay $700 Million Talc Probe Settlement; Moderna Rises on $6.7 Billion COVID-19 Vaccine Sales
MT
Moderna Insider Sold Shares Worth $4,500,450, According to a Recent SEC Filing
MT
Stéphane Bancel, CEO of Moderna: Merck-Moderna vaccine reduces risk of skin cancer recurrence
MT
Moderna CEO Stephane Bancel to Assume Responsibility for Sales, Marketing in 2024 Amid Preparations for Product Launches
MT
Moderna chief commercial officer steps down
RE
Moderna Announces Changes to Commercial Organization
CI
Moderna Chairman Afeyan on Industry Outlook, Strategy, AI
MT
Arbutus Biopharma Posts Q3 Net Loss, Lower Revenue; CEO to Retire, 24% Research Staff Cut
MT
Stéphane Bancel, CEO of Moderna: sales down, restructuring underway, acquisitions to come
MT
Lonza cuts 2024 margin target again after CEO departure
RE
Moderna Insider Sold Shares Worth $292,953, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. News Moderna, Inc.
  5. Insiders
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW